Characteristics2,3

  • Second most common form of focal dystonia
  • Causes bilateral involuntary eyelid closure and is centrally mediated
  • Progression of symptoms is common and may lead, in severe cases, to legal blindness
  • Stress can worsen symptoms
  • Symptoms may improve after sleep
  • Thought to be underdiagnosed and the actual incidence may be significantly higher
A pair of black boxing shoes with white strings

Symptoms4

  • Excessive blinking
  • Watering eyes
  • Light sensitivity
  • Dry eyes
  • Eye irritation

Reported incidence is 35,000 new cases every year worldwide3

Real Patient testimonials

Dona

Cynthia Is a 52-year-old Schoolteacher Who's Always up for Adventure

The life she's fighting for

During the school year, Cynthia lives her passion, teaching photography to teenagers. And in her off time, she loves a good thriller, often hosting her friends for book club. During her summers, Cynthia is all about traveling by RV and photographing the country with her husband, Jack.

Cynthia, a patient with blepharospasm, sitting on a stool talking about XEOMIN

The weigh-in

  • Cynthia began experiencing symptoms 6 years ago with eye twitching and more frequent, uncontrollable blinking
  • These symptoms became progressively worse, and Cynthia began to feel like it wasn't safe for her to drive
  • When teaching her students, or in social situations, Cynthia often feels self-conscious when it happens

Sparring with blepharospasm

  • Cynthia received treatment with a different botulinum toxin formulation for 4 years; however, it had recently begun to lose its efficacy and her symptoms were once again intruding into her life
Cynthia standing upright in a boxing ring
Never defeated, Cynthia was ready when her doctor suggested a change

Explore XEOMIN for the treatment of adult blepharospasm

Previously-Treated
Treatment-naïve
Worried about waning efficacy?
Consider XEOMIN
Learn More Back to Indications
50 unit, 100 unit, and 200 unit vials of XEOMIN

Dosing & Administration

For details on dosing and administration of XEOMIN for Cervial Dystonia, including injection locations and downloadable injection trackers

Learn more

Duration of Effect6-8

  • Long-lasting symptom relief may be possible with XEOMIN for blepharospasm
    • In an open-label clinical trial, the median treatment interval was 19.9 weeks
Change From Baseline in JRS Severity Subscore5
See Xeomin Safety
Worried about waning efficacy?
Consider XEOMIN
Learn More Back to Indications
JRS, Jankovic Rating Scale; U, Units.
50 unit, 100 unit, and 200 unit vials of XEOMIN

Dosing & Administration

For details on dosing and administration of XEOMIN for Cervial Dystonia, including injection locations and downloadable injection trackers

Learn more

Duration of Effect6-8

  • Long-lasting symptom relief may be possible with XEOMIN for blepharospasm
    • In an open-label clinical trial, the median treatment interval was 19.9 weeks
JRS Severity Subscore at Baseline and Week 67
See Xeomin Safety
Worried about waning efficacy?
Consider XEOMIN
Learn More Back to Indications

Missing values replaced with last observation carried forward.

The potency Units of XEOMIN are specific to the preparation and assay method utilized. They are not interchangeable with the other preparations of botulinum toxin products and, therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.

JRS, Jankovic Rating Scale; CI, confidence interval.

Common Adverse Reactions vs Placebo in Treatment-naїve Patients
In treatment-naïve patients, the most common adverse reactions affecting ≥6% and greater than placebo1
Adverse Reactions
Percentage of patients
XEOMIN
n=19
Placebo
n=20
Eye disorders
21
10
Eyelid ptosis
16
0
Common Adverse Reactions vs Placebo in Patients Previously Treated with Botox®
In patients previously treated with Botox, the most common adverse reactions affecting ≥5% and greater than placebo1
Adverse Reactions
Percentage of patients
XEOMIN
n=74
Placebo
n=34
Subjects with adverse reactions
70
62
Eye disorders
38
21
Eyelid ptosis
19
9
Dry eye
16
12
Visual impairment*
12
6
Gastrointestinal disorders
30
15
Dry mouth
16
3
Diarrhea
8
0
Infections and infestations
20
15
Nasopharyngitis
5
3
Respiratory tract infections
5
3
Nervous system disorders
14
9
Headache
7
3
General disorders and administration-site conditions
11
9
Respiratory, thoracic, and mediastinal disorders
11
3
Dyspnea
5
3

*Including vision blurred.
Learn About XEOMIN Dosing
Worried about waning efficacy?
Consider XEOMIN
Learn More Back to Indications
U, Units.

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2023.
  2. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247(10):787-792.
  3. Tsui JKC. Blepharospasm and hemifacial spasm. In: Brin MF, Comella C, Jankovic J, eds. Dystonia: Etiology, Clinical Features, and Treatment. New York, NY: Lippincott Williams & Wilkins; 2004:151-158.
  4. Blepharospasm. National Eye Institute website. Accessed June 18, 2021. https://nei.nih.gov/health/blepha/blepharospasm
  5. Mitsikostas DD, Dekundy A, Sternberg K, Pagan F. Safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. Neurology. 2019;92(suppl 15):S28.005.
  6. Data on file. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.
  7. Mitsikostas DD, Dekundy A, Hanschmann A, et al. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. Curr Med Res Opin. 2021;37(10):1761-1768.
  8. Truong DD, Gollomp SM, Jankovic J, et al; Xeomin US Blepharospasm Study Group. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm. J Neural Transm (Vienna). 2013;120(9):1345-1353.
  9. Mitsikostas DD, Dekundy A, Sternberg K, Althaus M, Pagan F. IncobotulinumtoxinA for the treatment of blepharospasm in toxin naïve subjects: a multi-center, double-blind, randomized, placebo-controlled trial. Adv Ther. 2020;37(10):4249-4265.
  10. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—a randomized trial. Mov Disord. 2011;26(8):1521-1528.
Back to Top
IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING
WARNING:
DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

INDICATIONS

XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in patients 2 years of age and older
  • Upper limb spasticity in adults
  • Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy
  • Cervical dystonia in adults
  • Blepharospasm in adults
IMPORTANT SAFETY INFORMATION (continued)
CONTRAINDICATIONS
  • Known hypersensitivity to any botulinum toxin product or to any of the components (human albumin, sucrose) in the formulation.
  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN are specific to the preparation and assay method utilized. Units of biological activity of Xeomin cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.
  • Serious hypersensitivity reactions (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea) have been reported with botulinum toxin products. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm: Reduced blinking from injection of botulinum toxin products into the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders. Patients with previous eye surgery should be carefully assessed for corneal sensation before treatment. Xeomin should be used with caution in patients at risk of developing narrow angle glaucoma. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for licensed albumin or albumin contained in other licensed products.
  • Use caution when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • Use caution when XEOMIN is used in patients who have marked facial asymmetry, with surgical alterations to the facial anatomy, pre-existing eyelid or eyebrow ptosis, when excessive weakness or atrophy is present in the target muscles, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (e.g., the inability to substantially lessen glabellar lines even by physically spreading them apart).
ADVERSE REACTIONS

The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea:
    • in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
    • in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
  • Upper Limb Spasticity
    • in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
    • in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
  • Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
  • Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth.
DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of XEOMIN.

USE IN PREGNANCY

XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN have not been established in pediatric patients for lower limb spasticity, cervical dystonia, or blepharospasm.

Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with chronic sialorrhea and upper limb spasticity. A pediatric assessment for XEOMIN in upper limb spasticity demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.

Visit www.xeomin.com to obtain the Full Prescribing Information and Medication Guide.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING
WARNING:
DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

INDICATIONS

XEOMIN® (incobotulinumtoxinA) for injection is indicated for the treatment of:

  • Chronic sialorrhea in patients 2 years of age and older
  • Upper limb spasticity in adults
  • Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy
  • Cervical dystonia in adults
  • Blepharospasm in adults
IMPORTANT SAFETY INFORMATION (continued)
CONTRAINDICATIONS
  • Known hypersensitivity to any botulinum toxin product or to any of the components (human albumin, sucrose) in the formulation.
  • Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN are specific to the preparation and assay method utilized. Units of biological activity of Xeomin cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.
  • Serious hypersensitivity reactions (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea) have been reported with botulinum toxin products. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of XEOMIN and institute appropriate medical therapy immediately.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) may be at increased risk for severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Cervical Dystonia: Treatment with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post- marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products. Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm: Reduced blinking from injection of botulinum toxin products into the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders. Patients with previous eye surgery should be carefully assessed for corneal sensation before treatment. Xeomin should be used with caution in patients at risk of developing narrow angle glaucoma. To decrease the risk for ectropion, XEOMIN should not be injected into the medial lower eyelid area.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases, CJD, or vCJD have ever been reported for licensed albumin or albumin contained in other licensed products.
  • Use caution when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • Use caution when XEOMIN is used in patients who have marked facial asymmetry, with surgical alterations to the facial anatomy, pre-existing eyelid or eyebrow ptosis, when excessive weakness or atrophy is present in the target muscles, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (e.g., the inability to substantially lessen glabellar lines even by physically spreading them apart).
ADVERSE REACTIONS

The most commonly observed adverse reactions at rates specified below and greater than placebo are:

  • Chronic Sialorrhea:
    • in adults (≥4% of patients): tooth extraction, dry mouth, diarrhea, and hypertension.
    • in pediatric patients (≥1% of patients): bronchitis, headache, and nausea/vomiting.
  • Upper Limb Spasticity
    • in adults (≥2% of patients): seizure, nasopharyngitis, dry mouth, and upper respiratory tract infection.
    • in pediatric patients (≥3% of patients): nasopharyngitis and bronchitis.
  • Cervical Dystonia in adults (≥5% of patients): dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.
  • Blepharospasm in adults (≥10% of patients): eyelid ptosis, dry eye, visual impairment, and dry mouth.
DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects.

The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of XEOMIN.

USE IN PREGNANCY

XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN have not been established in pediatric patients for lower limb spasticity, cervical dystonia, or blepharospasm.

Safety and effectiveness have been established in pediatric patients 2 to 17 years of age in patients with chronic sialorrhea and upper limb spasticity. A pediatric assessment for XEOMIN in upper limb spasticity demonstrates that XEOMIN is safe and effective in another pediatric population. However, XEOMIN is not approved for such patient population due to marketing exclusivity for another botulinum toxin.

Visit www.xeomin.com to obtain the Full Prescribing Information and Medication Guide.